EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease

Daphne de Korte, Menno Hoekstra iD

Biomolecules · 2025

DOI: 10.3390/biom15020185 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Daphne de Korte und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Gorlaeus Laboratories, Einsteinweg 55, 23…. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Neoplasms, Metabolic Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein arginine methyltransferase 1 (PRMT1) is the main PRMT family member involved in the formation of monomethylarginine and asymmetric dimethylarginine on its protein substrates. Many protein substrates of PRMT1 are key mediators of cell proliferation and oncogenesis. As such, the function of PRMT1 has been most prominently investigated in the context of cancer development. However, recent in vitro and in vivo studies have highlighted that PRMT1 may also promote metabolic disorders. With the current review, we aim to present an in-depth overview of how PRMT1 influences epigenetic modulation, transcriptional regulation, DNA damage repair, and signal transduction in cancer. Furthermore, we summarize the current knowledge regarding the role of PRMT1 in metabolic reprogramming, lipid metabolism, and glucose metabolism and describe the association of PRMT1 with numerous metabolic pathologies such as obesity, liver disease, and type 2 diabetes. It has become apparent that inhibiting the function of PRMT1 will likely serve as the most beneficial therapeutic approach, since several PRMT1 inhibitors have already been shown to exert positive effects on both cancer and metabolic disease in preclinical settings. However, pharmacological PRMT1 inhibition has not yet been shown to be therapeutically effective in clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesNeoplasmsMetabolic DiseasesHumansAnimalsEpigenesis, GeneticSignal TransductionRepressor Proteins

Stichwörter der Autor:innen

PRMT1cancerliver diseasemetabolismobesityprotein arginine methyltransferasetype 2 diabetes

Substanzen

Protein-Arginine N-MethyltransferasesPRMT1 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Gorlaeus Laboratories, Einsteinweg 55, 2333 CC Leiden, The Netherlands.

ORCID-Profile: Menno Hoekstra

Zitieren

APA

de Korte, D., & Hoekstra, M. (2025). Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease. Biomolecules. https://doi.org/10.3390/biom15020185

Vancouver

de Korte D, Hoekstra M. Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease. Biomolecules. 2025. doi:10.3390/biom15020185

BibTeX
@article{deKorte2025,
  author = {de Korte, Daphne and Hoekstra, Menno},
  title = {Protein Arginine Methyltransferase 1: A Multi-Purpose Player in the Development of Cancer and Metabolic Disease},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15020185}
}
Kostenlos starten →